Media Library

Thomas Schall
President, Chief Executive Officer & Chairman
ChemoCentryx

Preview:

"We aim to change the current treatment paradigm with precision medicine. Avacopan, our highly specific small molecule, inhibits chemoattractant receptors with a precise mechanism of action"